Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin and Tobramycin Powder in Acute Open Fractures
NCT05849090Phase 1Completed
- Sponsor
- University of Utah
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Deep Tissue Infection comparing Standard of Care with Vancomycin + Tobramycin (2 arms). Primary endpoints: Percent (%) positive deep tissue infections at 6 months and Percent (%) negative deep tissue infections at 6 months. Started Mar 2023; status: completed.
02
Drugs
vancomycintobramycin
03
Conditions
Deep Tissue Infection
Beyond the preview
Go deeper on NCT05849090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849090.